Wass J A, Thorner M O, Morris D V, Rees L H, Mason A S, Jones A E, Besser G M
Br Med J. 1977 Apr 2;1(6065):875-8. doi: 10.1136/bmj.1.6065.875.
Seventy-three patients with active acromegaly were treated for three to 25 months with bromocriptine 10-60 mg/day. Seventy-one patients showed symptomatic and objective clinical improvement. This included reduction in excessive sweating, hand and foot size, and the number of headaches; improved facial appearance; and increased energy and libido. Abnormal visual fields became normal in two patients, one of whom had concomitant radiotherapy. Mean circulating growth hormone levels, obtained by averaging serial samples through the day, fell by more than 7 microng/l or became undetectable in 58 patients (79%) but did not reach normal values: only 15 patients had mean levels on treatment of 5 microng/l or less. Twenty-three patients were diabetic before treatment, and glucose tolerance became normal in 15 and improved in a further five. Provided the drug was started slowly side effects were minor when compared with the considerable clinical benefit obtained.
73例活动性肢端肥大症患者接受了为期3至25个月的溴隐亭治疗,剂量为每日10 - 60毫克。71例患者出现了症状性和客观性的临床改善。这包括多汗症状减轻、手足尺寸减小、头痛次数减少;面部外观改善;精力和性欲增强。2例患者异常视野恢复正常,其中1例同时接受了放疗。通过对一天内系列样本进行平均得到的平均循环生长激素水平,在58例患者(79%)中下降超过7微克/升或降至检测不到,但未达到正常水平:只有15例患者治疗时的平均水平为5微克/升或更低。23例患者治疗前患有糖尿病,15例患者葡萄糖耐量恢复正常,另有5例有所改善。只要缓慢开始用药,与所获得的显著临床益处相比,副作用较小。